Credit Suisse’s Trillium Therapeutics Inc. TRIL Stock Holding History

Credit Suisse’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-315,046	Closed	-$5.53M	–	4769
2021 Q3	$5.53M	Buy	315,046 +247,234	+365%	+$2.89M	﹤0.01%	1976
2021 Q2	$658K	Sell	67,812 -18,929	-22%	-$178K	﹤0.01%	3665
2021 Q1	$932K	Buy	86,741 +16,842	+24%	+$208K	﹤0.01%	3367
2020 Q4	$1.03M	Buy	+69,899	New	+$1.01M	﹤0.01%	3325
2017 Q1	–	Sell	-25,382	Closed	-$143K	–	4165
2016 Q4	$143K	Buy	+25,382	New	+$253K	﹤0.01%	3890

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Credit Suisse's TRIL Position: Q4 2021 in Review

Credit Suisse sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 315,046 shares — an estimated $5.53M sold.

Credit Suisse first reported a position in TRIL in Q4 2016 and held it in 5 quarters. The position peaked at $5.53M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Credit Suisse reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Credit Suisse sold 315,046 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.53M.
Credit Suisse first reported a position in Trillium Therapeutics Inc. in Q4 2016 and held it in 5 quarters.
Credit Suisse's Trillium Therapeutics Inc. position peaked at $5.53M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.